Logo

Janssen Reports Submission of sBLA to the US FDA for Tremfya (guselkumab) to Treat Active Psoriatic Arthritis

Share this

Janssen Reports Submission of sBLA to the US FDA for Tremfya (guselkumab) to Treat Active Psoriatic Arthritis

Shots:

  • The sBLA is based on two P-III DISCOVER-1 & 2 studies assessing Tremfya (SC) in 381 & 739 patients with active PsA including prior treated patients with anti-TNF therapy and continued through 52wks. & biologic-naïve patients planning to continue through 100wks. respectively
  • The P-III DISCOVER-1 & 2 studies resulted in meeting their 1EPs i.e- ACR20 @24wks.- the safety profile is consistent with prior studies
  • Tremfya (guselkumab) is a mAb targeting p19 subunit of IL-23 and is the first approved selective IL-23 inhibitor- received the FDA’s approval for mod. to sev. plaque psoriasis in July’2017 with its anticipated MAA submission to EMA for PsA in H2’19

Click here to­ read full press release/ article

Ref: Johnson & Johnson | Image: Janssen 


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions